Skip to content
All news
Earnings

Abbott Laboratories Q2 2026 Earnings: Revenue Up, Profit Down – Still Below Fair Value?

Abbott Laboratories (ABT) released its Q2 2026 earnings, showing year-over-year revenue growth but declines in net income and earnings per share. The stock has rallied 12.66% over the past week and 14.51% over the past month, drawing attention to upcoming estimates.

July 23, 2026
2 min read
Source: Simply Wall St.
Share:

Key Numbers

revenue
higher year over year
net income
lower year over year
eps
lower year over year
7 day return
12.66%
30 day return
14.51%

Abbott Laboratories (ABT) reported its second-quarter 2026 earnings, with revenue increasing year over year while net income and earnings per share (EPS) declined. The mixed results have refocused attention on the stock, which recently rallied 12.66% in 7 days and 14.51% in 30 days.

Key Financial Results

MetricQ2 2026YoY Change
RevenueHigherIncrease
Net IncomeLowerDecrease
EPSLowerDecrease

Highlights from the Report

The company did not provide specific reasons for the decline in net income despite higher revenue, but it may be attributed to increased costs or expenses.

Future Guidance

No formal guidance was provided, but analysts are awaiting updates on future expectations.

Impact on the Stock

Despite lower profitability, ABT shares rose 12.66% over the past week and 14.51% over the past month, indicating investor optimism about future growth.

What This Means for Investors

The mixed earnings leave the question of whether the stock is still below fair value. Investors should monitor upcoming estimates and guidance to assess the opportunity.

Frequently Asked Questions

Revenue increased year over year, but the exact figure was not disclosed in the report.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.